A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 882-887

  Coleman, R E ^a   Biganzoli, L ^b   Canney, P ^c   Dirix, L ^d   Mauriac, L ^e   Chollet, P ^f   Batter, V ^b   Ngalula Kabanga, E ^b   Dittrich, C ^g   Piccart, M ^b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e INSTITUT BERGONIÉ   (France)

^f CENTRE JEAN PERRIN   (France)

^g LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Liposomal doxorubicin; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 33646485684     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.011     Document Type: Article

References (9)

1. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
2. Koukourakis M.I., Koukouraki S., Giatromanolaki A., et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta Oncol. 39 (2000) 207-211
3. Ransom M.R., Carmichael J., O'Byrne K., et al. Treatment of advanced breast cancer with sterically stabilised liposomal doxorubicin: results of a multicentre phase II trial. J. Clin. Oncol. 15 (1997) 3185-3191
4. O'Brien M., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004) 440-449
5. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. The Oncologist 8 Suppl. 2 (2003) 10-16
6. Hamilton A., Biganzoli L., Coleman R., et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx™, Doxil™) at a 6 weekly interval in patients with metastatic breast cancer. Ann. Oncol. 13 (2002) 910-918
7. Chao T.C., Wang W.S., Yen C.C., et al. A dose-escalating pilot study or sterically stabilised, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. Cancer Invest. 21 (2003) 967-968
8. 2. Ann. Oncol. 11 (2000) 1029-1033
9. Batist G., Ramakrishnan G., Rao C.S., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomised, multicentre trial of metastatic breast cancer. J. Clin. Oncol. 19 (2001) 1444-1454